April 26, 2017 10:17 AM EDT
News Briefing

An­a­lysts of­fer a luke­warm en­dorse­ment to Am­gen for PhI­II mi­graine da­ta; Ar­sa­nis rais­es $45.5M Se­ries D; Co­v­ance faces re­struc­tur­ing

Shehla Shakoor

Managing Director

→ An­a­lysts took a look at the da­ta on Am­gen’s lat­est Phase III for CGRP mi­graine drug erenum­ab (AMG334) and came away re­as­sured, but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times